Some Products May Appear Restricted
To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.
If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)
If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation; additional documentation will be requested for these items prior to shipment.
Specifications
- Description:Hydroxypyridinium Crosslinks HPLC Column, 1 column
- Cat. No.:102994-528
- Supplier no.:IC3201RP
Specifications
About this item
Hydroxypyridinium crosslinks HPLC column can be used with the HPLC kit and for 500 to 1000 samples.
- For use with hydroxypyridinium crosslinks HPLC assay kit
Pyridinium and deoxypyridinium are built as intramolecular crosslinkers during the maturation of collagen. During bone resorption collagen is degraded and the pyridinium-crosslinks are excreted. They are not reutilized by the body and excreted in the urine. The crosslinks are not released during the de novo synthesis of collagen. They are specific for resorptive processes. Neither PYD nor DPD are taken up by nutrition. Therefore the determination of the crosslinks is independent from the diet.
PYD is found in cartilage, ligaments and bone, whereas DPD is rather specific for bone. The crosslink excretion shows a strong circadian rhythm with a maximum in the early morning hours. Reliable data can be obtained with a 24 h or a creatinine corrected morning urine. An elevated crosslink excretion is shown in osteoporotic women. Crosslink levels decrease during treatment with estrogen (Seibel et al. 1994). Therefore they are suited for therapy monitoring (Ganero et al. 1994). The measurement of pyridinium crosslinks is an independent predictor for future bone fractures (Ganero et al. 1995). Increased crosslink concentrations are also described in patients with Paget’s Disease, primary hyperparathyroidism and bone metastasis.